Skip to main content

Matthew W. Tikonoff


[email protected]



Matt represents public and private companies and investors in a range of transactional and corporate matters, with a focus on mergers and acquisitions, capital markets transactions, securities law compliance and general corporate representation.  His experience includes advising clients in strategic acquisitions and divestitures, including private equity transactions, carve-out transactions and complex earn-out arrangements, as well as representing closely-held companies in exit transactions.  He also advises issuers in capital markets transactions, including initial public offerings and follow-on offerings.  Matt has experience counseling clients in a number of industries, including life sciences, medical technology, telecommunications, technology and retail.

During law school, he served as Articles Editor of the Suffolk University Law Review.

Matt is the lead Corporate Hiring Member for the firm’s Summer Associate Program in Boston.


  • Suffolk University Law School (JD, magna cum laude)
  • Boston College (BA)


Mergers & Acquisitions

  • Philips Healthcare in connection with numerous acquisitions and other strategic transactions.  Representative transactions include:
    • Divestiture of Philips’ Aging and Caregiving (ACG) business
    • Acquisition of Intact Vascular, the maker of the Tack specialized implantable device for treating peripheral artery disease
    • Acquisition of the teleradiology platform of Direct Radiology 
    • Acquisition of EPD Solutions, the innovator of a breakthrough cardiac imaging and navigation system
    • Acquisition of Remote Diagnostics Technologies, a UK-based innovator of advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management
    • Acquisition of Blue Willow Systems, a cloud-based senior living community resident safety platform
    • Acquisition of CardioProlific, a company developing catheter-based thrombectomy approaches to peripheral vascular disease
  • Netsmart Technologies, a health information technology provider, in connection with numerous acquisitions.  Representative transactions include:
    • Acquisition of SimpleLTC, a data analytics and consulting services firm
    • Acquisition of GPM, a Software-as-a-Service technology and services company
    • Acquisition of Tellus, a provider of electronic visit verification (EVV), mobile care delivery and claims processing technology
    • Acquisition of Quality In Real Time (QIRT), a post-acute health care consulting firm
    • Acquisition of McBee Associates, a healthcare consulting firm
    • Acquisition of Homecare Accounting Solutions, LLC, a cloud-based software company for home care agencies
    • Acquisition of Devero, Inc., a healthcare technology company specializing in home healthcare and hospice
    • Acquisition of HealthMEDX, a developer of electronic medical record (EMR) solutions
    • Acquisition of Trend Consulting Services, a provider of information technology outsourcing and infrastructure support services
    • Acquisition of Lavender & Wyatt Systems, a provider of enterprise behavioral health electronic medical records software and technology solutions
  • Viela Bio (Nasdaq:VIE) in its $3.05 billion sale to Horizon Therapeutics (Nasdaq: HZNP)
  • F-Star Therapeutics in its reverse merger with Spring Bank Pharmaceuticals (Nasdaq: SBPH)
  • Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
  • Patriot Energy Group, a retail electricity and natural gas management firm, in its strategic alliance with EMEX, LLC
  • Belmont Instrument Corporation, a leading provider of fluid warming infusion systems, in its recapitalization transaction with Audax Private Equity
  • Jacqueline's Wholesale Bakery, Inc., a leading manufacturer of frozen cookie dough for the in-store bakery and foodservice channels, in connection with its sale to Rich Product Corporation
  • Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
  • Associated Home Care, a private-duty home health aide provider, in its sale to Amedisys (NASDAQ: AMED)
  • Frazier Healthcare Ventures, a middle-market private equity firm, in its acquisition of a medical footware company
  • SiOnyx, a semiconductor process company, in its acquisition by a leading private equity firm
  • Edgile, a cybersecurity consulting firm, in a minority investment transaction with a leading private equity firm
  • A privately-held distributor of industrial supplies in its sale to a strategic competitor
  • Essilor International, an eyewear company, in its acquisition of Costa (NASDAQ: ATX)
  • FGX International, an eyewear company, in its acquisition of Stylemark
  • Dynasil Corporation of America (NASDAQ: DYSL) in the sale of its cancer medical probe business to Dilon Technologies and the sale of its x-ray fluorescence lead paint detector business to Protec
  • PTC (NASDAQ: PTC) in its acquisition of Enigma Information Systems
  • Ampersand Capital Partners in its acquisitions of numerous portfolio companies

Securities Offerings

  • Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $75 million follow-on offering  and its $10 million registered direct offering
  • Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $83.6 million initial public offering 
  • WAVE Life Sciences (NASDAQ: WVE) in its $102 million initial public offering
  • Lamar Advertising Company (NASDAQ: LAMR) in Rule 144A debt offerings and follow-on exchange offers
  • Stemline Therapeutics (NASDAQ: STML) in its $30 million initial public offering


Recognition & Awards

  • Chambers USA: Massachusetts – Corporate/Mergers & Acquisitions (2021 – 2022)
  • Greater Boston Chamber of Commerce’s Boston’s Future Leaders Program (2018)

Recent Insights

News & Press


Viewpoint Thumbnail
This article reviews the Delaware Court’s Akorn decision, which allowed a buyer to escape an acquisition transaction because of a material adverse change affecting the seller’s business.
Read more

News & Press

Press Release Thumbnail
Mintz took lead role for long-term client NanoView Biosciences in its sale to Unchained Labs, a portfolio company of The Carlyle Group. NanoView, through its ExoView technology, characterizes exosomes and the company’s LentiView platform complements Unchained Labs’ tools for gene therapy researchers working with lentivirus, which is an immunodeficiency virus that causes AIDS.
This in-depth article discusses the closely-watched Akorn, Inc. v. Fresenius Kabi AG lawsuit. The decision, allowing a German drug company to pull out of $4.75 billion deal to acquire a U.S. competitor, came from the Delaware Chancery Court – a key voice for businesses and their attorneys. Mintz Members Bret Leone-Quick and Matt Tikonoff are quoted extensively throughout the article providing third-party commentary.